ORR of PD‐1/PD‐L1 blockade were 17% for ESCC,51 11.2% for GC,52, 54 20% for HCC,59 and 0% for PDAC.60 dMMR tumors can be MSI‐H and show a somatic mutation frequency of more than 10‐100‐fold those of pMMR/microsatellite‐stable (MSS) tumors.66 Hence, dMMR/MSI‐H tumor is thought to have the potential to encode “non‐self” immunogenic antigens and is thought to respond well to immune checkpoint blockade. This evidence concerns the gene PDCD1 and neoplasm.